Literature DB >> 8852404

Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination.

J Simó Miñana1, M Gaztambide Ganuza, P Fernández Millán, M Peña Fernández.   

Abstract

Hepatitis B recombinant vaccine immunoresponsiveness was studied in 427 preadolescents vaccinated with a 0, 1 and 6 months vaccination schedule. AntiHBs postvaccination titres (measured one month after the last dose) were related to the following variables: sex; weight; height; and Quetelet index. The antiHBs postvaccination titres were used to predict the length of protection induced by the vaccine. All preadolescents developed antiHBs titres 10 IU l-1 and no statistically significant differences could be found between sexes. The relation study between antiHBs postvaccination levels and Quetelet index showed a statistically significant inverse correlation. According to the antiHBs postvaccination titres, the central 50% of the sample distribution would be protected during a period between 7.5 and 10.5 years. In pre-teenagers, the hepatitis B recombinant vaccine has proven to be highly immunogenic, obesity is a predictor of poor immunoresponse and this response is not influenced by sex. According to our results, we would propose the administration of a single booster dose 10 years after primary vaccination and thus protect these subjects during the period of greatest risk.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852404     DOI: 10.1016/0264-410x(95)00176-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

3.  A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B.

Authors:  M C Honorati; A Palareti; P Dolzani; C A Busachi; R Rizzoli; A Facchini
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 4.  Obesity: impact of infections and response to vaccines.

Authors:  C Tagliabue; N Principi; C Giavoli; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-30       Impact factor: 3.267

5.  Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States.

Authors:  Coleen K Cunningham; Bret J Rudy; Jiahong Xu; James Bethel; Bill G Kapogiannis; Sushma Ahmad; Craig M Wilson; Patricia M Flynn
Journal:  Pediatr Infect Dis J       Date:  2010-06       Impact factor: 2.129

6.  Reduced tetanus antibody titers in overweight children.

Authors:  Alon Eliakim; Christina Schwindt; Christina Swindt; Frank Zaldivar; Paolo Casali; Dan M Cooper
Journal:  Autoimmunity       Date:  2006-03       Impact factor: 2.815

Review 7.  The weight of obesity on the human immune response to vaccination.

Authors:  Scott D Painter; Inna G Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2015-07-08       Impact factor: 3.641

8.  High prevalence of hepatitis B non-immunity in paediatric non-alcoholic fatty liver disease patients.

Authors:  Minesh Mehta; Crystal Slaughter; Stavra A Xanthakos; Rohit Kohli
Journal:  Dig Liver Dis       Date:  2014-04-16       Impact factor: 4.088

Review 9.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Altered or Impaired Immune Response to Hepatitis B Vaccine in WNIN/GR-Ob Rat: An Obese Rat Model with Impaired Glucose Tolerance.

Authors:  Prathibha Bandaru; Hemalatha Rajkumar; Giridharan Nappanveettil
Journal:  ISRN Endocrinol       Date:  2011-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.